Other equities research analysts also recently issued reports about the stock. B. Riley assumed coverage on shares of Mazor Robotics in a research note on Thursday, October 6th. They set a neutral rating and a $25.00 price objective for the company. Standpoint Research assumed coverage on shares of Mazor Robotics in a research note on Friday, July 8th. They set a buy rating and a $30.00 price objective for the company. Zacks Investment Research upgraded shares of Mazor Robotics from a sell rating to a hold rating and set a $22.00 price objective for the company in a research note on Tuesday, July 19th. Finally, Barclays PLC boosted their price objective on shares of Mazor Robotics from $16.00 to $23.00 and gave the stock an overweight rating in a research note on Thursday, July 14th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock has a consensus rating of Hold and an average target price of $26.25.
Mazor Robotics (NASDAQ:MZOR) traded down 4.2941% during midday trading on Wednesday, reaching $23.5245. 63,264 shares of the company’s stock were exchanged. The stock’s 50 day moving average is $23.36 and its 200 day moving average is $18.23. Mazor Robotics has a 52 week low of $8.31 and a 52 week high of $26.55. The firm’s market capitalization is $509.85 million.
Mazor Robotics (NASDAQ:MZOR) last released its quarterly earnings data on Tuesday, August 2nd. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.02. Mazor Robotics had a negative net margin of 60.75% and a negative return on equity of 42.30%. The company earned $8.30 million during the quarter, compared to the consensus estimate of $8.51 million. During the same period in the previous year, the firm earned ($0.05) earnings per share. Mazor Robotics’s revenue for the quarter was up 6.4% on a year-over-year basis. On average, analysts expect that Mazor Robotics will post ($0.71) EPS for the current fiscal year.
Hedge funds have recently bought and sold shares of the stock. Cookson Peirce & Co. Inc. bought a new stake in Mazor Robotics during the second quarter valued at about $192,000. Trellus Management Company LLC boosted its stake in Mazor Robotics by 11.6% in the second quarter. Trellus Management Company LLC now owns 23,982 shares of the company’s stock valued at $431,000 after buying an additional 2,500 shares in the last quarter. Menta Capital LLC boosted its stake in Mazor Robotics by 81.9% in the first quarter. Menta Capital LLC now owns 37,482 shares of the company’s stock valued at $466,000 after buying an additional 16,879 shares in the last quarter. Candriam Luxembourg S.C.A. bought a new stake in Mazor Robotics during the second quarter valued at about $1,079,000. Finally, Iguana Healthcare Management LLC boosted its stake in Mazor Robotics by 384.6% in the first quarter. Iguana Healthcare Management LLC now owns 121,151 shares of the company’s stock valued at $1,507,000 after buying an additional 96,151 shares in the last quarter. 18.71% of the stock is currently owned by hedge funds and other institutional investors.
About Mazor Robotics
Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.
Receive News & Ratings for Mazor Robotics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.